[Pharmwaste] Concentrations of prioritized pharmaceuticals
ineffluents from 50 large wastewater treatment plants in the US
andimplications for risk estimation
Catherine Zimmer
zenllc at usfamily.net
Thu Dec 5 16:03:54 EST 2013
Hi Diane,
>From everything I’ve read it would take a multitude of treatment regimens to address the plethora of pharmaceuticals (and other contaminants) in our wastewater systems. And, if we got breakdown, what would those breakdown products look like? Would they be biologically active? What kind of pollutants would they be?
I hate to sound like a broken record, but a better strategy is to reduce and eliminate these things at the source. First, we stop using our surface waters as dumps. Industry has to re-use their own water, they can’t dump into rivers, lakes, oceans. WWTP, also re-use water. Households get educated on health improvements that don’t use drugs and MD support alternative treatments and less toxic/persistent pharmaceuticals when necessary. Individual households treat their sewage to remove rx. While this is a large undertaking, it seems ultimately a better outcome than trying to treat everything being dumped into the water.
Very truly yours,
Catherine Zimmer, MS, BSMT
Principal
Zimmer Environmental Improvement LLC
Ph: 651.645.7509
From: Buxbaum, Diane
Sent: Tuesday, December 03, 2013 2:44 PM
To: DeBiasi, Deborah (DEQ) ; pharmwaste at lists.dep.state.fl.us
Cc: abuxbaum at downtownwomen.com ; cbuxbaum at sandiaprep.org ; ATL-LEADERS at LISTS.SIERRACLUB.ORG
Subject: RE: [Pharmwaste] Concentrations of prioritized pharmaceuticals ineffluents from 50 large wastewater treatment plants in the US andimplications for risk estimation
I am ccing some nongovernmental environmental activists on this email Wow, how depressing. Were most or all of these plants secondary plants? Were any tertiary? Are there any ideas of nonprohibitive methods for reducing or eliminating the discharge of these pharmaceuticals into the receiving bodies? Would, in areas where there is the land, exposure to sunlight and ponds allow for the breakdown of these drugs (and how dangerous might those products be)? Probably not possible in most urban areas and even where possible very costly.
Diane D. Buxbaum, MPH
Environmental Scientist
U.S. Environmental Protection Agency,
Region 2
Division of Enforcement and Compliance Assistance
290 Broadway (21 East)
New York, NY 10007
buxbaum.diane at epa.gov
Phone 212-637-3919
Fax 212-637-4086
From: pharmwaste-bounces at lists.dep.state.fl.us [mailto:pharmwaste-bounces at lists.dep.state.fl.us] On Behalf Of DeBiasi, Deborah (DEQ)
Sent: Tuesday, December 03, 2013 3:21 PM
To: pharmwaste at lists.dep.state.fl.us
Subject: [Pharmwaste] Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation
Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation
Mitchell S. Kostich*, Angela L. Batt, James M. Lazorchak
Ecological Exposure Research Division, National Exposure Research Laboratory, U.S. Environmental Protection Agency, 26 W. Martin Luther King Drive, Cincinnati, OH 45268, USA
ABSTRACT
We measured concentrations of 56 active pharmaceutical ingredients (APIs) in effluent samples from 50 large wastewater treatment plants across the US. Hydrochlorothiazide was found in every sample. Metoprolol, atenolol, and carbamazepine were found in over 90% of the samples. Valsartan had the highest concentration (5300 ng/L), and also had the highest average concentration (1600 ng/L) across all 50 samples. Estimates of potential risks to healthy human adults were greatest for six anti-hypertensive APIs (lisinopril, hydrochlorothiazide, valsartan, atenolol, enalaprilat, and metoprolol), but nevertheless suggest risks of exposure to individual APIs as well as their mixtures are generally very low. Estimates of potential risks to aquatic life were also low for most APIs, but suggest more detailed study of potential ecological impacts from four analytes (sertraline, propranolol, desmethylsertraline, and valsartan).
Published by Elsevier Ltd.
Deborah L. DeBiasi
Email: Deborah.DeBiasi at deq.virginia.gov
WEB site address: www.deq.virginia.gov
Virginia Department of Environmental Quality
Office of Water Permits
Industrial Pretreatment/Whole Effluent Toxicity (WET) Program
PPCPs, EDCs, and Microconstituents
http://www.deq.virginia.gov/Programs/Water/PermittingCompliance/PollutionDischargeElimination/Microconstituents.aspx
Mail: P.O. Box 1105, Richmond, VA 23218
Location: 629 E. Main Street, Richmond, VA 23219
PH: 804-698-4028 FAX: 804-698-4032
--------------------------------------------------------------------------------
---
Note: As a courtesy to other listserv subscribers, please post messages to the listserv in plain text format to avoid the garbling of messages received by digest recipients.
---
TO SUBSCRIBE, go to: http://lists.dep.state.fl.us/cgi-bin/mailman/listinfo/pharmwaste
TO UNSUBSCRIBE, DO NOT REPLY TO THE LISTSERV. Please send an e-mail to pharmwaste-unsubscribe at lists.dep.state.fl.us -- the subject line and body of the e-mail should be blank.
If you believe you may be subscribed with a different email address, please visit the subscriber listing at http://lists.dep.state.fl.us/cgi-bin/mailman/roster/pharmwaste
FOR PROBLEMS: Contact List Administrator Laurie.Tenace at dep.state.fl.us
SEND MAIL to the list server at: pharmwaste at lists.dep.state.fl.us
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://lists.dep.state.fl.us/pipermail/pharmwaste/attachments/20131205/53de1fa0/attachment.htm
-------------- next part --------------
A non-text attachment was scrubbed...
Name: not available
Type: image/png
Size: 164 bytes
Desc: not available
Url : http://lists.dep.state.fl.us/pipermail/pharmwaste/attachments/20131205/53de1fa0/attachment.png
More information about the Pharmwaste
mailing list